Mandate

Vinge advises Cell Impact AB (publ) in connection with a directed share issue

Vinge has advised Cell Impact AB (publ) in connection with a directed share issue, whereby Cell Impact receives proceeds of SEK 175 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to finance Cell Impact’s continued path towards commercialization and expand the production capacity in the new factory in order to pave the way for expanded serial production.

Vinge’s team has consisted of Johan Larsson, Dain Hård Nevonen, Rikard Lindahl, Maria Dahlin-Kolvik, Joel Magnusson, Vilhelm Rondahl and Linnea Petersson.

Related

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge advises Studentbostäder i Norden AB (publ) in connection with its issuance of bonds in an amount of SEK 500 million and its early redemption of outstanding bonds

Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
March 12, 2026